TL;DR
An integrated pan-cancer analysis of PABPC1L expression and function in 33 human malignant tumors identified PABPC1L as exhibiting oncogenic properties and is proposed to function as a key regulator of tumorigenesis and immunotherapy resistance.
CDC20B may contribute to tumor progression in a context-dependent manner, with its prognostic impact varying across cancer types, and promoter hypomethylation emerges as a potential epigenetic driver of overexpression.
Pan-cancer survival analysis demonstrated that elevated KIAA1467 expression significantly predicted shortened overall survival in BRCA and multiple other tumor types, and KIAA1467 displayed distinct expression patterns across cancers, with prominent upregulation in BRCA.
PPAP2C exhibits the most significant overexpression pattern across 33 cancer types and was significantly associated with advanced clinical stages and aggressive subtypes (HER2+ and TNBC).
BCAT1 expression was significantly upregulated in most malignancies, and high expression was associated with worse OS and DFS in multiple cancer types, highlighting its potential as a pan-cancer biomarker and therapeutic target.
ISG20L2 is aberrantly upregulated and associated with malignant biological features and immune-related characteristics in gastric cancer, supporting its potential role as a pro-oncogenic regulator and a candidate molecular indicator requiring further clinical validation.
A systematic pan-cancer characterization of MEX3A is provided and supports its potential role as a prognostic biomarker and a hypothesis-generating candidate for future mechanistic and clinical validation, as well as suggesting that MEX3A may participate in RNA regulatory networks and tumor-immune microenvironment inte...
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
